BiotechTube

Motolimod + Nivolumab

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HNSCC

Conditions

HNSCC

Trial Timeline

Oct 15, 2021 → Mar 25, 2022

NCT ID
NCT04272333

About Motolimod + Nivolumab

Motolimod + Nivolumab is a phase 1 stage product being developed by Bristol Myers Squibb for HNSCC. The current trial status is terminated. This product is registered under clinical trial identifier NCT04272333. Target conditions include HNSCC.

What happened to similar drugs?

0 of 2 similar drugs in HNSCC were approved

Approved (0) Terminated (1) Active (1)
🔄Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®)AkesoPhase 3
❌LymphoseekNavidea BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04272333Phase 1Terminated

Competing Products

18 competing products in HNSCC

See all competitors
ProductCompanyStageHype Score
AZD2936AstraZenecaPhase 2
42
pepinemab + pembrolizumabMerckPhase 1/2
32
PembrolizumabMerckPhase 2
39
Pembrolizumab, CetuximabMerckPhase 2
35
eftilagimod alpha + pembrolizumab (KEYTRUDA®)MerckPhase 2
35
Cetuximab/avelumabMerckPhase 2
42
Ulevostinag + PembrolizumabMerckPhase 2
35
Nivolumab + Cisplatin + CetuximabBristol Myers SquibbPhase 1
29
Nivolumab + Relatlimab + IpilimumabBristol Myers SquibbPhase 2
42
Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®)AkesoPhase 3
47
FDC fianlimab+cemiplimab + Cemiplimab + PlaceboRegeneron PharmaceuticalsPhase 2
42
GTAEXS617 + SoCRecursion PharmaceuticalsPhase 1/2
33
Ficerafusp alfa + PembrolizumabBicara TherapeuticsPhase 2
36
INBRX-106 + PembrolizumabInhibrx BiosciencesPhase 2/3
39
Tipifarnib + AlpelisibKura OncologyPhase 1/2
26
STRO-004 + PembrolizumabSutro BiopharmaPhase 1
26
DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2Phio PharmaceuticalsPhase 1
23
LymphoseekNavidea BiopharmaceuticalsPhase 3
22